2023 World Conference on Lung Cancer (Posters)-P2.06. Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3

P2.06. Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3 - PDF(Slides)

Back to course

Pdf Summary

Cemiplimab, an anti-PD-1 antibody, has shown promise in the treatment of advanced non-small cell lung cancer (NSCLC) with liver metastases, according to an exploratory analysis presented at the International Association for the Study of Lung Cancer – World Conference on Lung Cancer. The analysis included data from two phase 3 trials, EMPOWER-Lung 1 and EMPOWER-Lung 3 Part 2.<br /><br />Liver metastases in NSCLC are associated with poor response to chemotherapy and reduced survival times. The analysis showed that cemiplimab-based therapy, either as monotherapy or in combination with chemotherapy, provided a relative benefit over chemotherapy alone in patients with liver metastases. The overall survival (OS) was 20.4 months with cemiplimab versus 7.6 months with chemotherapy in patients with liver metastases and PD-L1 Tumor Proportion Score (TPS) 50%. Additionally, the progression-free survival (PFS) was longer with cemiplimab-based therapy compared to chemotherapy.<br /><br />The safety profile of cemiplimab-based therapy in patients with liver metastases was similar to that of the overall study population. Treatment-emergent adverse events were common, but generally manageable.<br /><br />These findings highlight the potential of cemiplimab as a first-line treatment option for advanced NSCLC with liver metastases. The study provides important long-term results from randomized, phase 3 trials, which are relatively rare in patients with baseline liver metastases. Further research is needed to confirm these findings and optimize treatment strategies for this patient population.<br /><br />The studies were funded by Regeneron Pharmaceuticals, Inc. and Sanofi, and medical writing support was provided by Prime. The authors disclosed possible conflicts of interest and responsibility for all opinions, conclusions, and data interpretation lies with the authors.

Asset Subtitle

Ana Baramidze

Meta Tag

Speaker Ana Baramidze

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

Cemiplimab

anti-PD-1 antibody

advanced non-small cell lung cancer

NSCLC

liver metastases

chemotherapy

overall survival

progression-free survival

safety profile

first-line treatment